NAPLEX Question of the Day

Dapagliflozin reduced the composite of cardiovascular death or heart failure hospitalization versus placebo, without demonstrating a mortality benefit over 12 months.

Dapagliflozin caused a significant reduction in all-cause mortality compared with placebo.

Because acute kidney injury was similar between groups, dapagliflozin can be considered safe across all stages of chronic kidney disease.

As an observational study, this trial cannot support causal conclusions about dapagliflozin.